Clinical and cost-effectiveness of diverse posthospitalisation pathways for COVID-19: a UK evaluation using the PHOSP-COVID cohort

Briggs, AH; Ibbetson, A; Walters, A; Houchen-Wolloff, L; Armstrong, N; Emerson, T; Gill, R; Hastie, C; Little, P; Overton, C; Pimm, J; Poinasamy, K; Singh, S; Walker, S; Leavy, OC; Richardson, M; Elneima, O; McAuley, H; Shikotra, A; Singapuri, A; Sereno, M; Saunders, RM; Harris, VC; Greening, NJ; Raman, B

COVID-19 Collection

Journal article

Clinical and cost-effectiveness of diverse posthospitalisation pathways for COVID-19: a UK evaluation using the PHOSP-COVID cohort

Abstract:: Background: Long covid has emerged as a complex health condition for millions of people worldwide following the COVID-19 pandemic. Previously, we have categorised healthcare pathways for patients after discharge from hospital with COVID-19 across 45 UK sites. The aim of this work was to estimate the clinical and cost-effectiveness of these pathways. Methods: We examined prospectively collected data from 1013 patients at 12 months postdischarge on whether they felt fully recovered (self-report), number of newly diagnosed conditions (NDC), quality of life (EuroQoL-five dimension-five level (EQ-5D-5L) utility score compared with pre-COVID estimate) and healthcare resource costs (healthcare records). An analysis of the cost-effectiveness was performed by combining the healthcare resource cost and 1-year EQ-5D (giving a quality-adjusted life-year (QALY)) using statistical models that accounted for observed confounding. Results: At 1 year, 29% of participants felt fully recovered, and 41% of patients had an NDC. The most comprehensive services, where all patients could potentially access assessment, rehabilitation and mental health services, were more clinically effective when compared with either no service or light touch services (mean (SE) QALY 0.789 (0.012) vs 0.725 (0.026)), with an estimated cost per QALY of £1700 (95% uncertainty interval: dominated to £24 800). Conclusion: Our analysis supports the need for proactive, stratified, comprehensive follow-up, particularly assessment and rehabilitation for adults after hospitalisation with COVID-19, showing these services are likely to be both clinically and cost-effective according to commonly accepted thresholds.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Briggs, A. H., Ibbetson, A., Walters, A., Houchen-Wolloff, L., Armstrong, N., Emerson, T., Gill, R., Hastie, C., Little, P., Overton, C., Pimm, J., Poinasamy, K., Singh, S., Walker, S., Leavy, O. C., Richardson, M., Elneima, O., McAuley, H., Shikotra, A., … Raman, B. (2025). Clinical and cost-effectiveness of diverse posthospitalisation pathways for COVID-19: a UK evaluation using the PHOSP-COVID cohort. BMJ Open Respiratory Research, 12(1).

MLA Style

Briggs, AH, et al. “Clinical and Cost-Effectiveness of Diverse Posthospitalisation Pathways for COVID-19: a UK Evaluation Using the PHOSP-COVID Cohort.” BMJ Open Respiratory Research, vol. 12, no. 1, 2025.

Chicago Style

Briggs, AH, A Ibbetson, A Walters, et al. 2025. “Clinical and Cost-Effectiveness of Diverse Posthospitalisation Pathways for COVID-19: a UK Evaluation Using the PHOSP-COVID Cohort.” BMJ Open Respiratory Research 12 (1).
Print